Showing results (371-380 of 385) with videos related to

Sort By:
Pageof 39
Water Research X|December 15, 2023
Mitigating risks and maximizing sustainability of treated wastewater reuse for irrigationDavid Yalin, Hillary A Craddock, Shmuel Assouline, et al.
The Lancet. Oncology|May 3, 2005
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trialLuisa L Villa, Ronaldo L R Costa, Carlos A Petta, et al.
Nature Communications|August 1, 2020
The electron affinity of astatineDavid Leimbach, Julia Karls, Yangyang Guo, et al.
Physical Review Letters|June 23, 2018
Probing Sizes and Shapes of Nobelium Isotopes by Laser SpectroscopyS Raeder, D Ackermann, H Backe, et al.
Vaccine|June 7, 2006
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18Luisa L Villa, Kevin A Ault, Anna R Giuliano, et al.
Cancer Prevention Research (Philadelphia, Pa.)|October 1, 2009
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesionsSusanne K Kjaer, Kristján Sigurdsson, Ole-Erik Iversen, et al.
BMJ (Clinical Research Ed.)|July 22, 2010
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial, Joakim Dillner, Susanne K Kjaer, et al.
Human Vaccines|October 27, 2009
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infectionSven-Eric Olsson, Susanne K Kjaer, Kristján Sigurdsson, et al.
The Journal of Infectious Diseases|February 25, 2009
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 yearsCosette M Wheeler, Susanne K Kjaer, Kristján Sigurdsson, et al.
Vaccine|October 22, 2008
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccineElmar A Joura, Susanne K Kjaer, Cosette M Wheeler, et al.
Pageof 39